Abstract
Phase III platform trials are increasingly used to evaluate a sequence of treatments for a specific disease. Traditional approaches to structure such trials tend to focus on the sequential questions rather than the performance of the entire enterprise. We consider two-stage trials where an early evaluation is used to determine whether to continue with an individual study. To evaluate performance, we use the ratio of expected wins (RW), that is, the expected number of reported efficacious treatments using a two-stage approach compared to that using standard phase III trials. We approximate the test statistics during the course of a single trial using Brownian Motion and determine the optimal stage 1 time and type I error rate to maximize RW for fixed power. At times, a surrogate or intermediate endpoint may provide a quicker read on potential efficacy than use of the primary endpoint at stage 1. We generalize our approach to the surrogate endpoint setting and show improved performance, provided a good quality and powerful surrogate is available. We apply our methods to the design of a platform trial to evaluate treatments for COVID-19 disease.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
No funding was required for this work
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
N/A
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
dean.follmann{at}nih.gov
michael.proschan{at}nih.gov
Data Availability
There's no data in this manuscript.